By analyzing longitudinal samples of MM patients undergoing total therapy, we identified a significant increase in NFκB pathway activity in MM PC that survived first-line total therapy, and second-line chemotherapy-based induction therapy after relapse. The gene discussed is NFKB1; the disease is Miyoshi myopathy.